Authors

Sho Yoshimoto, Daiki Kato*, Satoshi Kamoto, Kie Yamamoto, Masaya Tsuboi, Masahiro　Shinada, Namiko Ikeda, Yuiko Tanaka, Ryohei Yoshitake, Shotaro Eto, Kohei Saeki, James Chambers, Yuko Hashimoto, Kazuyuki Uchida, Ryohei Nishimura, Takayuki Nakagawa

Abstract

Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various human cancers. HER2-targeted therapies showed clinical responses in humans with HER2-positive tumors. The incidence of canine primary lung cancer (cPLC) is increasing, but there are no effective systemic therapies for dogs with late-stage cPLC. HER2-targeted therapy could be an option for cPLC, but HER2 expression in cPLC remains unknown. We evaluated HER2 expression in cPLC. Immunohistochemical analysis revealed that 3 samples (19%) scored 3+; 8 (50%), 2+; 5 (31%); and 1+ and 0 (0%), 0. Of the cPLC tissues, 69% were HER2 positive (scored ≥2+). These data would lead to further evaluation of the role of HER2 in cPLC as a mechanism of malignancy and therapeutic target.

Paper Information

Journal
: The Journal of Veterinary Medical Science
DOI
: 10.1292/jvms.20-0026
: https://www.jstage.jst.go.jp/article/jvms/advpub/0/advpub_20-0026/_article/